Edition:
United States

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

2.67USD
8 Dec 2017
Change (% chg)

$0.21 (+8.54%)
Prev Close
$2.46
Open
$2.45
Day's High
$2.83
Day's Low
$2.45
Volume
14,456
Avg. Vol
6,826
52-wk High
$35.70
52-wk Low
$2.24

Latest Key Developments (Source: Significant Developments)

Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial
Monday, 24 Jul 2017 08:30am EDT 

July 24 (Reuters) - Dare Bioscience Inc ::Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial.Final details will be negotiated under a separate agreement.  Full Article

Cerulean Pharma estimates cash, cash equivalents as of June 30,
Monday, 17 Apr 2017 04:45pm EDT 

April 17 (Reuters) - Cerulean Pharma Inc ::Cerulean Pharma-estimates cash, cash equivalents as of june 30, assuming has not consummated transactions under novartis apa or dar*pa, to be $4 million-$6 million.Cerulean Pharma-in event that dar*pa deal does not close board may elect to dissolve co,liquidate assets whether under title 7 or title 11 of u.s. Code.Cerulean Pharma-if board decides to dissolve assets,would be required to pay all of debts, obligations, among others, before distribution to stockholders.Cerulean Pharma-expects that amount of cash left, if any, to distribute to stockholders would be materially less than expected amounts set forth as of june 30.  Full Article

Cerulean Pharma and Daré Bioscience enter into stock purchase agreement
Monday, 20 Mar 2017 08:00am EDT 

Cerulean Pharma Inc : Cerulean pharma and daré bioscience enter into stock purchase agreement . Cerulean pharma inc - cerulean enters into two agreements to sell assets . Cerulean pharma inc- cerulean pays off debt facility and announces reduction in force . Cerulean pharma inc - stockholders of daré bioscience will receive shares of newly issued cerulean common stock . Cerulean pharma inc - outstanding daré bioscience options and convertible securities will be assumed by cerulean . Cerulean pharma inc - sabrina martucci johnson to be named ceo of combined company . Cerulean pharma inc - transaction has been unanimously approved by boards of directors of both companies . Cerulean pharma inc - cerulean sold its clinical product candidates, crlx101 and crlx301, for $1.5 million to bluelink pharmaceuticals . Cerulean pharma inc - cerulean also entered into an agreement with novartis . Cerulean pharma inc-in connection with the transactions, it is paying off its debt facility with hercules capital, inc. . Cerulean pharma inc - novartis will acquire all rights to cerulean's dynamic tumor targeting(tm) platform for $6 million . Cerulean pharma-board of combined company will consist of five members, three to be designated by daré and two to be designated by cerulean . Cerulean pharma inc- upon close of proposed transaction, board of directors of combined company will consist of five members.  Full Article

Cerulean Pharma reports Q3 2016 financial results
Thursday, 3 Nov 2016 04:11pm EDT 

Cerulean Pharma Inc - : Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . In quarter, announced 5-target collaboration with novartis to combine Co's proprietary NDC technology with Novartis-selected compounds .Cerulean reports third quarter 2016 financial results and provides corporate update.  Full Article

Cerulean Pharma says reducing workforce by about 48 pct
Thursday, 18 Aug 2016 04:01pm EDT 

Cerulean Pharma Inc : Cerulean announces reduction in force . Says reducing its workforce by about 48 pct, to a total of 23 full-time equivalent employees . Says expects reduction plan to be substantially completed by end of 2016 . Says workforce reduction is designed to reduce operating expenses while co refocuses its clinical strategy for CRLX101 .Expects reduction in force to result in about $5 million in reduced annualized operating expenses.  Full Article

Cerulean says has enough cash to fund planned ops into Q2 2017
Thursday, 4 Aug 2016 04:05pm EDT 

Cerulean Pharma Inc : Cerulean reports second quarter 2016 corporate highlights and financial results . Believes its cash and cash equivalents are sufficient to fund its planned operations into q2 of 2017 .Qtrly net loss attributable to stockholders for q2 was $10.9 million, compared to net loss attributable to common stockholders of $9.9 million.  Full Article

Cerulean Pharma receives FDA fast track designation for ovarian cancer treatment
Tuesday, 19 Jul 2016 07:30am EDT 

Cerulean Pharma Inc : Receives FDA fast track designation for CRLX101 for the treatment of platinum-resistant ovarian cancer .Expects to provide an update on CRX101 at European Society For Medical Oncology 2016 Congress.  Full Article

BRIEF-Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial

* Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial